zanubrutinib   Click here for help

GtoPdb Ligand ID: 9861

Synonyms: BGB-3111 | BGB3111 | Brukinsa® | compound 27b [US9447106]
Approved drug Immunopharmacology Ligand
zanubrutinib is an approved drug (FDA (2019), EMA (2021))
Compound class: Synthetic organic
Comment: Zanubrutinib (BGB-3111) is a potent, selective and irreversible BTK inhibitor that was developed by BeiGene for utility in the treatment of B cell cancers, such as non-Hodgkin's lymphoma and chronic lymphocytic leukemia (CLL) [1,4].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 102.48
Molecular weight 471.23
XLogP 4.5
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C=CC(=O)N1CCC(CC1)[C@@H]1CCNc2n1nc(c2C(=O)N)c1ccc(cc1)Oc1ccccc1
Isomeric SMILES C=CC(=O)N1CCC(CC1)[C@@H]1CCNc2n1nc(c2C(=O)N)c1ccc(cc1)Oc1ccccc1
InChI InChI=1S/C27H29N5O3/c1-2-23(33)31-16-13-18(14-17-31)22-12-15-29-27-24(26(28)34)25(30-32(22)27)19-8-10-21(11-9-19)35-20-6-4-3-5-7-20/h2-11,18,22,29H,1,12-17H2,(H2,28,34)/t22-/m0/s1
InChI Key RNOAOAWBMHREKO-QFIPXVFZSA-N
Bioactivity Comments
In a cellular assay, zanubrutinib inhibits BTK with an IC50 of 20nM [5].
Selectivity at enzymes
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
Bruton tyrosine kinase Hs Inhibitor Inhibition 8.7 pIC50 - 5
pIC50 8.7 (IC50 2x10-9 M) [5]
Description: Inhibition of the enzymatic activity of recombinant human BTK in a TR-FRET assay.